Brooktree Capital Management Has $536,000 Stake in Cardlytics, Inc. (NASDAQ:CDLX)

Brooktree Capital Management boosted its holdings in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 24.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,642 shares of the company’s stock after buying an additional 33,169 shares during the period. Cardlytics comprises 0.4% of Brooktree Capital Management’s portfolio, making the stock its 23rd largest holding. Brooktree Capital Management owned approximately 0.34% of Cardlytics worth $536,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Cardlytics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after buying an additional 57,805 shares during the period. Marshall Wace LLP lifted its holdings in shares of Cardlytics by 6.8% during the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock valued at $6,685,000 after acquiring an additional 52,081 shares during the period. GSA Capital Partners LLP boosted its stake in shares of Cardlytics by 1,273.2% in the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after purchasing an additional 354,474 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Cardlytics by 711.9% during the 2nd quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares in the last quarter. Finally, Kent Lake Capital LLC bought a new position in Cardlytics during the 1st quarter valued at about $3,622,000. Institutional investors own 68.10% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CDLX. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. Northland Capmk downgraded Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Lake Street Capital cut Cardlytics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $18.00 to $5.00 in a report on Thursday, August 8th. Northland Securities cut Cardlytics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $7.00 to $5.00 in a report on Friday, August 16th. Finally, Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.92.

Insider Activity at Cardlytics

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the firm’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the transaction, the chief executive officer now owns 178,519 shares in the company, valued at approximately $687,298.15. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 43,573 shares of company stock worth $151,612. 4.40% of the stock is owned by insiders.

Cardlytics Stock Performance

Shares of NASDAQ:CDLX opened at $3.86 on Thursday. The stock has a market capitalization of $196.17 million, a P/E ratio of -0.63 and a beta of 1.61. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 1-year low of $2.89 and a 1-year high of $20.52. The business has a 50-day moving average price of $3.72 and a two-hundred day moving average price of $6.50.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The firm had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The business’s revenue for the quarter was down 15.1% on a year-over-year basis. During the same period last year, the firm earned ($0.26) earnings per share. Equities analysts predict that Cardlytics, Inc. will post -1.72 earnings per share for the current year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.